Proteomics International Laboratories (ASX:PIQ) is focused on predictive diagnostics for diabetic kidney disease.
The company continues on a path to commercialisation as it advances deals with partners in Singapore and China to bring its PromarkerD, which is patented in both countries, to the Asian market.
PromarkerD means the company can accurately predict if someone will get the disease in the next four years so they can take lifestyle and medication action immediately to cut their risks.
Proteomics International is rated at the forefront of using proteomics technology for diabetes diagnostics worldwide.
Find out more from Richard Lipscombe at Proactive's CEO Sessions.
Click on city below to register by email
- Melbourne: Tuesday 11th April.
- Sydney: Wednesday 12th April.
- Email Pauline here.
- Call office on (02) 9280 0700.
Presenter list
- Intermin Resources (ASX:IRC): MD Jon Price
- Southern Gold (ASX:SAU): MD Simon Mitchell
- Proteomics International Laboratories (ASX:PIQ): MD Richard Lipscombe
- Dimerix (ASX:DXB): CEO Kathy Harrison
- Novogen (ASX:NRT): CEO Dr James Garner (Presenting in Melbourne only)
- Aspire Mining (ASX:AKM): MD David Paull (Presenting in Sydney only)